We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Human Embryonic Stem Cell-Derived Cardiomyocyte Therapy for Chronic Ischemic Left Ventricular Dysfunction (HECTOR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05068674
Recruitment Status : Recruiting
First Posted : October 6, 2021
Last Update Posted : September 19, 2022
Sponsor:
Collaborator:
California Institute for Regenerative Medicine (CIRM)
Information provided by (Responsible Party):
Joseph C. Wu, Stanford University

Brief Summary:
This clinical study will utilize a new cell therapy approach (Human embryonic stem cells derived cardiomyocytes or hESC-CMs) to improve survival and cardiac function in patients with chronic left ventricular dysfunction secondary to MI (Myocardial Infarction).

Condition or disease Intervention/treatment Phase
Chronic Ischemic Left Ventricular Dysfunction Drug: Human Embryonic Stem Cell-Derived Cardiomyocyte 50M cells Drug: Human Embryonic Stem Cell-Derived Cardiomyocyte 150 cells Drug: Human Embryonic Stem Cell-Derived Cardiomyocyte 300M cells Phase 1

Detailed Description:
The phase I dose-escalation pilot study is intended as an initial safety assessment to establish the MTD prior to the phase II randomized, double-blinded, placebo-controlled study. An estimated eighteen (18) patients in phase I who are scheduled to undergo cardiac catheterization and have met all inclusion/exclusion criteria will be enrolled.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Phase I will be a standard 3+3 dose-escalation study to evaluate 3 doses of allogeneic hESC-CMs
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Randomized Pilot Study of Human Embryonic Stem Cell-Derived Cardiomyocytes (hESC-CMs) in PaTients With ChrOnic Ischemic Left VentRicular Dysfunction Secondary to Myocardial Infarction (HECTOR)
Actual Study Start Date : March 22, 2022
Estimated Primary Completion Date : October 2025
Estimated Study Completion Date : October 2025

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Cohort 1
Low dose (50M cells)
Drug: Human Embryonic Stem Cell-Derived Cardiomyocyte 50M cells
50 million (M) cells delivered in a dose of 5M cells per injection over 10 injections.
Other Name: Human ESC-CMs

Active Comparator: Cohort 2
Medium dose (150M cells)
Drug: Human Embryonic Stem Cell-Derived Cardiomyocyte 150 cells
150M cells delivered in a dose of 15M cells per injection over 10 injections
Other Name: Human ESC-CMs

Active Comparator: Cohort 3
High dose (300M cells)
Drug: Human Embryonic Stem Cell-Derived Cardiomyocyte 300M cells
300M cells delivered in a dose of 30M per injection over 10 injections
Other Name: Human ESC-CMs




Primary Outcome Measures :
  1. The maximum tolerated dose (MTD) among 3 dose levels of allogeneic human embryonic stem cell-derived cardiomyocytes (hESC-CMs) [ Time Frame: 3 Years ]
    The primary endpoints are safety and feasibility. The feasibility of preparing and delivering the study product, as well as collecting cardiac MRI variables in subjects will be assessed.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Be ≥ 21 and < 80 years of age.
  • Provide written informed consent.
  • Have a diagnosis of chronic ischemic left ventricular dysfunction secondary to MI as defined by previous myocardial infarction documented by an imaging study demonstrating coronary artery disease with corresponding areas of akinesis, dyskinesis, or severe hypokinesis.
  • Be a candidate for cardiac catheterization within 5 to 10 weeks of screening.
  • Have been treated with appropriate maximal medical therapy for heart failure or postinfarction left ventricular dysfunction. For beta-blockade, the patient must have been on a stable dose of a clinically appropriate beta-blocker for 3 months. For angiotensinconverting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) or angiotensin receptor neprilysin inhibitors (ARNIs) or have appropriate medical indication precluding use of one or both of these agents, the patient must have been on a stable dose of a clinically appropriate agent for 1 month or within no more than doubling the dose of any of ARB, ACE inhibitors, and ARNIs over the last 3 months.
  • Left ventricular ejection fraction below 40%.
  • Class II/III NYHA symptoms of heart failure within the 6 months prior to baseline testing.
  • Hospitalization in the past 6 months or NT pro-BNP > 1200 pg/mL, or >1600 pg/mL if atrial fibrillation was present.
  • Automated implantable cardioverter-defibrillator (AICD) in place.

Exclusion Criteria:

  • Have a baseline glomerular filtration rate < 35 ml/min/1.73 m2
  • Have a known, serious radiographic contrast allergy.
  • Have a prosthetic aortic valve or heart constrictive device.
  • Have a documented presence of aortic stenosis (aortic stenosis graded as 1.5 cm2 or less).
  • Have a documented presence of moderate to severe aortic insufficiency (echocardiographic assessment of aortic insufficiency graded as ≥+2).
  • Have evidence of a life-threatening arrhythmia in the absence of a defibrillator (nonsustained ventricular tachycardia ≥ 20 consecutive beats or complete second- or third-degree heart block in the absence of a functioning pacemaker) or QTc interval > 550 ms on screening ECG.
  • AICD firing in the past 60 days prior to enrollment.
  • Be eligible for or require coronary artery revascularization.
  • Have a hematologic abnormality as evidenced by hematocrit < 25%, white blood cell < 2,500/µl, or platelet values < 100,000/µl without another explanation.
  • Have liver dysfunction, as evidenced by enzymes (AST and ALT) greater than three times the ULN.
  • Have a coagulopathy (INR > 1.3) not due to a reversible cause (i.e., Coumadin). Patients on Coumadin will be withdrawn 5 days before the procedure and confirmed to have an INR < 1.3. Patients who cannot be withdrawn from Coumadin will be excluded from enrollment.
  • Have known allergies to penicillin or streptomycin.
  • Be an organ transplant recipient.
  • Have a history of organ or cell transplant rejection.
  • Have a clinical history of malignancy within 5 years (i.e., patients with prior malignancy must be disease-free for 5 years), except curatively-treated basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma.
  • Have a non-cardiac condition that limits lifespan to < 1 year.
  • Be on chronic therapy with immunosuppressant medication, such as corticosteroids or TNFα antagonists.
  • Be serum-positive for HIV, hepatitis BsAg, or viremic hepatitis C.
  • Be currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial.
  • Be a female patient who is pregnant, nursing, or have child-bearing potential but is not using effective birth control.
  • Tested positive for SARS-CoV-2 within the last 30 days

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05068674


Contacts
Layout table for location contacts
Contact: Joseph C. Wu, MD, PhD (650) 736-2246 joewu@stanford.edu
Contact: Evgenios Neofytou, MD (650) 736-2246 neofytou@stanford.edu

Locations
Layout table for location information
United States, California
Stanford Hospital and Clinics Recruiting
Palo Alto, California, United States, 94305
Sponsors and Collaborators
Joseph C. Wu
California Institute for Regenerative Medicine (CIRM)
Layout table for additonal information
Responsible Party: Joseph C. Wu, Professor of Medicine and Radiology., Stanford University
ClinicalTrials.gov Identifier: NCT05068674    
Other Study ID Numbers: 60978
First Posted: October 6, 2021    Key Record Dates
Last Update Posted: September 19, 2022
Last Verified: September 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Ventricular Dysfunction
Ventricular Dysfunction, Left
Ischemia
Pathologic Processes
Heart Diseases
Cardiovascular Diseases